Scandinavian ChemoTech’s subsidiary signs its first commercial contract for the US veterinary market
ChemoTech’s Animal Care division Vetiqure AB signs a contract with FloridaWild Veterinary Hospital (“FloridaWild”) in Deland, Florida as a direct result of a successful trade show in Orlando, which generated many leads.
The contract with FloridaWild includes access to our vetIQure™ TSE device during an initial evaluation period and a commercial purchase of our treatment kits. In addition to the purchase of the treatment kits an order for the device will be placed following a successful evaluation. The joint goal with the agreement is to establish a Centre of Excellence with FloridaWild where clinical data and protocols for different species can be found and evaluated.
This agreement is a result from the VMX 2022 trade show in Orlando Florida, where Vetiqure AB presented the vetIQure™ and its patented TSE technology. FloridaWild is a veterinary hospital well known for its holistic and innovative perspective on Animal Care. An excellent fit for the first commercial installation for our unique and innovative TSE technology.
“We are very pleased to partner with Vetiqure to contribute to the body of evidence and work toward our shared goal of developing innovative therapies to help pets live their best lives.”- says Dr. Pamela Schrager, Medical Director, FloridaWild Veterinary Hospital
“The traction we have in the US at the moment and the interest we’ve received from other countries is very promising. Growth potentials like this will allow us to improve and expand our production capacity and our logistics to match the increased demand. We will now allocate resources to our Animal Care business in the US, Europe and the Middle East to ensure that we take full advantage of the commercial and clinical opportunities in front of us.” - says Mohan Frick, CEO ChemoTech & Vetiqure
Read more about FloridaWild Veterinary Hospital – www.floridawildvethospital.com
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-02-2022 08:45 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
